페르옥시레독신 1

PRDX1
사용 가능한 구조
PDB	Ortholog 검색: PDBe RCSB
PDB ID 코드 목록
	2RII, 3HY2, 4XCS
식별자
에일리어스	PRDX1, MSP23, NKEF-A, NKEFA, PAGA, PAGB, PRX1, PRXI, TDPX2, Peroxiredoxin 1
외부 ID	OMIM : 176763 MGI : 99523 HomoloGene : 99789 GenCard : PRDX1
유전자 위치(인간)
크르.	1번 염색체(인간)
끝.	45,542,732 bp
유전자 위치(마우스)
크르.	4번 염색체(쥐)
끝.	116,558,019 bp
RNA발현패턴
	상단 표시 위치:
	갑상선 우엽; ; 갑상선 좌엽; ; 안검결막; ; 신경절 융기; ; 잇몸; ; 구강; ; 랑게르한스 섬; ; 우부신; ; 좌부신; ; 오른쪽 폐;
	추가 참조 표현식 데이터
	추가 참조 표현식 데이터
유전자 존재론
분자 함수	항산화 활성; GO:0001948 단백질 결합; 페르옥시레독신 활성; 동일단백질결합; 산화환원효소활성; 티오레독신페르옥시다아제활성; 페르옥시다아제활성; RNA결합; 카드헤린 결합;
셀룰러 컴포넌트	세포질; 세포; 흑색체; 미엘린 칼집; 미토콘드리아; 세포외 엑소좀; 핵; GO:0005578 세포외 매트릭스; 세포외 공간;
생물학적 과정	골격계 발달; 슈퍼옥시드 라디칼 제거; 산화 스트레스에 대한 반응; 망막 항상성; 적혈구 항상성; 과산화수소 이화 과정; 세포군 증식; 응력 활성화 MAPK 캐스케이드 조절; 자연 킬러 세포 매개 세포독성; 세포 산화 환원 항상성; 자연킬러세포활성화; 활성 산소종에 대한 반응; 산화 스트레스에 대한 세포 반응; NIK/NF-kappaB 신호 조절; 백혈구활성화;
	출처:아미고 / QuickGO
맞춤법
	5052
	18477
	ENSG00000117450
	ENSMUSG000028691
	Q06830
	P35700
	NM_181697; NM_001202431; NM_002574; NM_181696
	NM_011034
	NP_001189360; NP_002565; NP_859047; NP_859048
	NP_035164
	위키데이터
인간 보기/편집	마우스 표시/편집

페르옥시레독신-1은 PRDX1 ^[5]^[6]유전자에 의해 인간에게 암호화되는 단백질이다.

기능.

이 유전자는 과산화수소와 알킬 하이드로페록시드를 ^[7]감소시키는 항산화효소의 과산화효소의 과산화리독신 계열의 일원을 암호화합니다.암호화된 단백질은 세포에서 항산화 보호 역할을 할 수 있으며 CD8(+) T세포의 항바이러스 활성에 기여할 수 있습니다.이 단백질은 증식 효과가 있을 수 있으며 암의 발생이나 진행에 영향을 미칠 수 있습니다.이 ^[6]유전자에 대해 동일한 단백질을 코드하는 세 가지 전사 변형이 확인되었다.

상호 작용

페르옥시레독신 1은 PRDX4와 ^[8]상호작용하는 것으로 나타났다.화학단백질접근법에 따르면 페르옥시레독신1이 오넬라스테론의 ^[9]주요 타깃이다.

임상적 의의

산화 스트레스와 싸우는 효소로서, 페르옥시레독신은 건강과 ^[10]질병에서 중요한 역할을 합니다.LPS 또는 TNF-alpha에 ^[11]의해 자극되었을 때 일부 세포에 의해 퍼옥시레독신1 및 퍼옥시레독신2가 방출되는 것으로 나타났다.방출된 과산화리독신은 염증성 사이토카인을 ^[11]생성하기 위해 작용할 수 있다.췌장암에서는 과산화리데옥신1의 수치가 높아져 잠재적으로 이 ^[12]질환의 진단과 예후에 대한 지표가 될 수 있다.일부 암종류에서는 과산화리데옥신1이 종양억제제로서 기능하는 것으로 판정되었으며, 다른 연구결과에 따르면 과산화리데옥신1은 ^[13]특정 인간암에서 과발현된다.최근 연구에 따르면 과산화리데옥신1은 식도 ^[13]편평상피암에서 mTOR/p70S6K 경로를 조절함으로써 종양유전에 관여할 수 있다.인간 폐암 ^[14]악성종양에는 과산화리데옥신1과 과산화리데옥신4의 발현패턴이 관여한다.또한 과산화리데옥신1은 ^[15]염증을 촉진하는 역할을 하기 때문에 급성호흡곤란증후군의 병인에 중요한 역할을 할 수 있는 것으로 나타났다.

레퍼런스

^ ^a ^b ^c GRCh38: 앙상블 릴리즈 89: ENSG00000117450 - 앙상블, 2017년 5월
^ ^a ^b ^c GRCm38: 앙상블 릴리즈 89: ENSMUSG000028691 - 앙상블, 2017년 5월
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Prospéri MT, Ferbus D, Karczinski I, Goubin G (May 1993). "A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins". The Journal of Biological Chemistry. 268 (15): 11050–6. doi:10.1016/S0021-9258(18)82090-7. PMID 8496166.
^ ^a ^b "Entrez Gene: PRDX1 peroxiredoxin 1".
^ Wu, C; Dai, H; Yan, L; Liu, T; Cui, C; Chen, T; Li, H (July 2017). "Sulfonation of the resolving cysteine in human peroxiredoxin 1: A comprehensive analysis by mass spectrometry". Free Radical Biology & Medicine. 108: 785–792. doi:10.1016/j.freeradbiomed.2017.04.341. PMC 5564515. PMID 28450148.
^ Jin DY, Chae HZ, Rhee SG, Jeang KT (Dec 1997). "Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation". The Journal of Biological Chemistry. 272 (49): 30952–61. doi:10.1074/jbc.272.49.30952. PMID 9388242.
^ Margarucci L, Monti MC, Tosco A, Esposito R, Zampella A, Sepe V, Mozzicafreddo M, Riccio R, Casapullo A (Jan 2015). "Theonellasterone, a steroidal metabolite isolated from a Theonella sponge, protects peroxiredoxin-1 from oxidative stress reactions". Chemical Communications. 51 (9): 1591–3. doi:10.1039/c4cc09205h. PMID 25503482. S2CID 11393982.
^ El Eter E, Al-Masri AA (May 2015). "Peroxiredoxin isoforms are associated with cardiovascular risk factors in type 2 diabetes mellitus". Brazilian Journal of Medical and Biological Research. 48 (5): 465–9. doi:10.1590/1414-431X20144142. PMC 4445671. PMID 25742636.
^ ^a ^b Mullen L, Hanschmann EM, Lillig CH, Herzenberg LA, Ghezzi P (2015). "Cysteine Oxidation Targets Peroxiredoxins 1 and 2 for Exosomal Release through a Novel Mechanism of Redox-Dependent Secretion". Molecular Medicine. 21: 98–108. doi:10.2119/molmed.2015.00033. PMC 4461588. PMID 25715249.
^ Cai CY, Zhai LL, Wu Y, Tang ZG (Feb 2015). "Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer". European Journal of Surgical Oncology. 41 (2): 228–35. doi:10.1016/j.ejso.2014.11.037. PMID 25434328.
^ ^a ^b Gong F, Hou G, Liu H, Zhang M (Feb 2015). "Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma". Medical Oncology. 32 (2): 455. doi:10.1007/s12032-014-0455-0. PMID 25579166. S2CID 5123492.
^ Jiang H, Wu L, Mishra M, Chawsheen HA, Wei Q (2014). "Expression of peroxiredoxin 1 and 4 promotes human lung cancer malignancy". American Journal of Cancer Research. 4 (5): 445–60. PMC 4163610. PMID 25232487.
^ Liu D, Mao P, Huang Y, Liu Y, Liu X, Pang X, Li Y (2014). "Proteomic analysis of lung tissue in a rat acute lung injury model: identification of PRDX1 as a promoter of inflammation". Mediators of Inflammation. 2014: 1–14. doi:10.1155/2014/469358. PMC 4082880. PMID 25024510.

추가 정보

Wood ZA, Schröder E, Robin Harris J, Poole LB (Jan 2003). "Structure, mechanism and regulation of peroxiredoxins". Trends in Biochemical Sciences. 28 (1): 32–40. doi:10.1016/S0968-0004(02)00003-8. PMID 12517450.
Sauri H, Butterfield L, Kim A, Shau H (Mar 1995). "Antioxidant function of recombinant human natural killer enhancing factor". Biochemical and Biophysical Research Communications. 208 (3): 964–9. doi:10.1006/bbrc.1995.1428. PMID 7702627.
Shau H, Butterfield LH, Chiu R, Kim A (1994). "Cloning and sequence analysis of candidate human natural killer-enhancing factor genes". Immunogenetics. 40 (2): 129–34. doi:10.1007/BF00188176. PMID 8026862. S2CID 7778993.
Kawai S, Takeshita S, Okazaki M, Kikuno R, Kudo A, Amann E (Apr 1994). "Cloning and characterization of OSF-3, a new member of the MER5 family, expressed in mouse osteoblastic cells". Journal of Biochemistry. 115 (4): 641–3. doi:10.1093/oxfordjournals.jbchem.a124388. PMID 8089076.
Shau H, Kim A (Feb 1994). "Identification of natural killer enhancing factor as a major antioxidant in human red blood cells". Biochemical and Biophysical Research Communications. 199 (1): 83–8. doi:10.1006/bbrc.1994.1197. PMID 8123050.
Prospéri MT, Apiou F, Dutrillaux B, Goubin G (Jan 1994). "Organization and chromosomal assignment of two human PAG gene loci: PAGA encoding a functional gene and PAGB a processed pseudogene". Genomics. 19 (2): 236–41. doi:10.1006/geno.1994.1053. PMID 8188254.
Wen ST, Van Etten RA (Oct 1997). "The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity". Genes & Development. 11 (19): 2456–67. doi:10.1101/gad.11.19.2456. PMC 316562. PMID 9334312.
Jin DY, Chae HZ, Rhee SG, Jeang KT (Dec 1997). "Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation". The Journal of Biological Chemistry. 272 (49): 30952–61. doi:10.1074/jbc.272.49.30952. PMID 9388242.
Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, Weitz JI, Austin RC (Aug 1999). "Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells". Blood. 94 (3): 959–67. doi:10.1182/blood.V94.3.959.415k20_959_967. PMID 10419887.
Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, Omura K, Suzuki H, Yoshida H (Oct 1999). "Peroxiredoxin I expression in human thyroid tumors". Cancer Letters. 145 (1–2): 127–32. doi:10.1016/S0304-3835(99)00243-8. PMID 10530780.
Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ (2001). "Overexpression of peroxiredoxin in human breast cancer". Anticancer Research. 21 (3B): 2085–90. PMID 11497302.
Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, Cai T, Zhang X, Xiao HS, Qu J, Liu F, Huang QH, Cheng ZH, Li NG, Du JJ, Hu W, Shen KT, Lu G, Fu G, Zhong M, Xu SH, Gu WY, Huang W, Zhao XT, Hu GX, Gu JR, Chen Z, Han ZG (Dec 2001). "Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver". Proceedings of the National Academy of Sciences of the United States of America. 98 (26): 15089–94. Bibcode:2001PNAS...9815089X. doi:10.1073/pnas.241522398. PMC 64988. PMID 11752456.
Kim SH, Fountoulakis M, Cairns N, Lubec G (2002). Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. Journal of Neural Transmission. Supplementum. pp. 223–35. doi:10.1007/978-3-7091-6262-0_18. ISBN 978-3-211-83704-7. PMID 11771746.
Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, Aebersold R, Benahmed M, Louisot P, Lunardi J (May 2002). "Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site". The Journal of Biological Chemistry. 277 (22): 19396–401. doi:10.1074/jbc.M106585200. PMID 11904290.
Chang TS, Jeong W, Choi SY, Yu S, Kang SW, Rhee SG (Jul 2002). "Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation". The Journal of Biological Chemistry. 277 (28): 25370–6. doi:10.1074/jbc.M110432200. PMID 11986303.
Wagner E, Luche S, Penna L, Chevallet M, Van Dorsselaer A, Leize-Wagner E, Rabilloud T (Sep 2002). "A method for detection of overoxidation of cysteines: peroxiredoxins are oxidized in vivo at the active-site cysteine during oxidative stress". The Biochemical Journal. 366 (Pt 3): 777–85. doi:10.1042/BJ20020525. PMC 1222825. PMID 12059788.
Shen C, Nathan C (Feb 2002). "Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells". Molecular Medicine. 8 (2): 95–102. doi:10.1007/BF03402079. PMC 2039972. PMID 12080185.
Yang KS, Kang SW, Woo HA, Hwang SC, Chae HZ, Kim K, Rhee SG (Oct 2002). "Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid". The Journal of Biological Chemistry. 277 (41): 38029–36. doi:10.1074/jbc.M206626200. PMID 12161445.
Geiben-Lynn R, Kursar M, Brown NV, Addo MM, Shau H, Lieberman J, Luster AD, Walker BD (Jan 2003). "HIV-1 antiviral activity of recombinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin family". The Journal of Biological Chemistry. 278 (3): 1569–74. doi:10.1074/jbc.M209964200. PMID 12421812.

외부 링크

PDB for UniProt: Q06830(Peroxiredoxin-1)에서 PDBe-KB에 있는 모든 구조 정보의 개요.

[refGRCh38Ensembl-1] GRCh38: 앙상블 릴리즈 89: ENSG00000117450 - 앙상블, 2017년 5월

[refGRCm38Ensembl-2] GRCm38: 앙상블 릴리즈 89: ENSMUSG000028691 - 앙상블, 2017년 5월

[3] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[4] "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[pmid8496166-5] Prospéri MT, Ferbus D, Karczinski I, Goubin G (May 1993). "A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins". The Journal of Biological Chemistry. 268 (15): 11050–6. doi:10.1016/S0021-9258(18)82090-7. PMID 8496166.

[entrez-6] "Entrez Gene: PRDX1 peroxiredoxin 1".

[7] Wu, C; Dai, H; Yan, L; Liu, T; Cui, C; Chen, T; Li, H (July 2017). "Sulfonation of the resolving cysteine in human peroxiredoxin 1: A comprehensive analysis by mass spectrometry". Free Radical Biology & Medicine. 108: 785–792. doi:10.1016/j.freeradbiomed.2017.04.341. PMC 5564515. PMID 28450148.

[pmid9388242-8] Jin DY, Chae HZ, Rhee SG, Jeang KT (Dec 1997). "Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation". The Journal of Biological Chemistry. 272 (49): 30952–61. doi:10.1074/jbc.272.49.30952. PMID 9388242.

[9] Margarucci L, Monti MC, Tosco A, Esposito R, Zampella A, Sepe V, Mozzicafreddo M, Riccio R, Casapullo A (Jan 2015). "Theonellasterone, a steroidal metabolite isolated from a Theonella sponge, protects peroxiredoxin-1 from oxidative stress reactions". Chemical Communications. 51 (9): 1591–3. doi:10.1039/c4cc09205h. PMID 25503482. S2CID 11393982.

[10] El Eter E, Al-Masri AA (May 2015). "Peroxiredoxin isoforms are associated with cardiovascular risk factors in type 2 diabetes mellitus". Brazilian Journal of Medical and Biological Research. 48 (5): 465–9. doi:10.1590/1414-431X20144142. PMC 4445671. PMID 25742636.

[cite_PMID|_25715249-11] Mullen L, Hanschmann EM, Lillig CH, Herzenberg LA, Ghezzi P (2015). "Cysteine Oxidation Targets Peroxiredoxins 1 and 2 for Exosomal Release through a Novel Mechanism of Redox-Dependent Secretion". Molecular Medicine. 21: 98–108. doi:10.2119/molmed.2015.00033. PMC 4461588. PMID 25715249.

[12] Cai CY, Zhai LL, Wu Y, Tang ZG (Feb 2015). "Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer". European Journal of Surgical Oncology. 41 (2): 228–35. doi:10.1016/j.ejso.2014.11.037. PMID 25434328.

[cite_PMID|_25579166-13] Gong F, Hou G, Liu H, Zhang M (Feb 2015). "Peroxiredoxin 1 promotes tumorigenesis through regulating the activity of mTOR/p70S6K pathway in esophageal squamous cell carcinoma". Medical Oncology. 32 (2): 455. doi:10.1007/s12032-014-0455-0. PMID 25579166. S2CID 5123492.

[14] Jiang H, Wu L, Mishra M, Chawsheen HA, Wei Q (2014). "Expression of peroxiredoxin 1 and 4 promotes human lung cancer malignancy". American Journal of Cancer Research. 4 (5): 445–60. PMC 4163610. PMID 25232487.

[15] Liu D, Mao P, Huang Y, Liu Y, Liu X, Pang X, Li Y (2014). "Proteomic analysis of lung tissue in a rat acute lung injury model: identification of PRDX1 as a promoter of inflammation". Mediators of Inflammation. 2014: 1–14. doi:10.1155/2014/469358. PMC 4082880. PMID 25024510.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

Search